Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor

NCT03884972 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Request by sponsor due to no enrollment of participants on study

Conditions

Refractory Chronic Lymphocytic Leukemia
Refractory Small Lymphocytic Lymphoma

Interventions

DRUG: Trabectedin
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]